Retaplase plus abciximab improves non-fatal outcomes, but not overall survival in people with diabetes and acute ST-segment elevation myocardial infarction - 24/08/11
Abstract |
Question |
In people with diabetes and ST-segment elevation myocardial infarction, is half-dose reteplase plus abciximab more effective than reteplase alone?
Study design |
Secondary analysis of multicentre randomised controlled trial.
Main results |
For mortality at 30 days or 1 year, there was no significant difference between groups (see Table 1). Reteplase plus abciximab significantly reduced the risk of reinfarction, or recurrent ischaemia or angina compared with reteplase alone.
| ||||||||||||||||||||||||
Authors’ conclusions |
Although treatment with reteplase plus abciximab did not provide a survival benefit for people with diabetes and ST-segment elevation myocardial infarction compared with reteplase alone, nonfatal outcomes including reinfarction and recurrent ischaemia were substantially reduced.
Le texte complet de cet article est disponible en PDF.Keywords : Diabetes, Acute myocardial infarction, Myocardial reperfusion, Fibrinolytic therapy, Randomised controlled trial
Plan
 | Abstracted from: Gurm HS, Lincoff AM, Lee D et al. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. J Am Coll Cardiol 2004; 43: 542–548. |
Vol 8 - N° 4
P. 230-231 - août 2004 Retour au numéro
Article précédent
- Intravenous magnesium sulphate does not improve survival or disability outcomes in people with stroke
- Scott Selco, Bruce Ovbiagele
- Rate of major complications is higher in laparoscopic than abdominal hysterectomy but quality of life improves with both procedures
- Lee A Learman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?